Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling

Kim,Jong Bin; Lee,Minjong; Park,Seo‑Young; Lee,Seulki; Kim,Hye Ri; Lee,Hyo‑Suk; Yoon,Jung‑Hwan; Kim,Yoon Jun

doi:10.3892/mmr.2015.4422

Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling

Authors:
- Jong Bin Kim
- Minjong Lee
- Seo‑Young Park
- Seulki Lee
- Hye Ri Kim
- Hyo‑Suk Lee
- Jung‑Hwan Yoon
- Yoon Jun Kim
View Affiliations

Affiliations: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 110‑799, Republic of Korea, Biomedical Research Institute, Seoul National University Hospital, Seoul 110‑799, Republic of Korea
Published online on: October 9, 2015 https://doi.org/10.3892/mmr.2015.4422
Pages: 8247-8252

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sorafenib is a systemic chemotherapeutic agent for advanced hepatocellular carcinoma (HCC). The aim of the present study was to evaluate the anticancer effect of sorafenib in cancer stem cell‑like cells, such as side population (SP) cells, in HCC and to analyze the signaling pathway for drug‑resistance. To evaluate the anticancer effects of sorafenib, Huh7 and Huh‑BAT cells were treated with sorafenib, fluorouracil (5‑FU), and sorafenib plus 5‑FU. These cells were examined for growth rates, the SP fraction, sphere‑forming efficacy and expression of c‑Jun N‑terminal kinase (JNK) signaling molecules. Sorafenib and 5‑FU treatment decreased growth rates in Huh7 and Huh‑BAT cells; however, the treatments exerted different effects in SP cells and on the expression levels of JNK signaling molecules. Treatment with 5‑FU increased the SP cell number and upregulated the expression of JNK signaling molecules. By contrast, sorafenib decreased the SP cell number and downregulated the expression of JNK signaling molecules. No significant differences in sphere‑forming efficacy were observed subsequent to 5‑FU and sorafenib treatment in Huh7 and Huh‑BAT cells. These results indicate that sorafenib exerted anticancer effects in HCC and SP cells by targeting JNK signaling.

View Figures

View References

1	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
2	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JD, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. New Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
3	Lang L: FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology. 134:3792008.PubMed/NCBI
4	Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, et al: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 12:7271–7278. 2006. View Article : Google Scholar : PubMed/NCBI
5	Min L, He B and Hui L: Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol. 21:10–20. 2011. View Article : Google Scholar
6	Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
7	Scartozzi M, Faloppi L, Svegliati Baroni G, Loretelli C, Piscaglia F, Iavarone M, Toniutto P, Fava G, De Minicis S, Mandolesi A, et al: VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study. Int J Cancer. 135:1247–1256. 2014. View Article : Google Scholar : PubMed/NCBI
8	Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
9	Xue C, Huang Y, Huang PY, Yu QT, Pan JJ, Liu LZ, Song XQ, Lin SJ, Wu JX, Zhang JW, et al: Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 24:1055–1061. 2013. View Article : Google Scholar
10	Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Bartolozzi C and Ricci S: Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 69:773–780. 2012. View Article : Google Scholar
11	Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
12	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
13	Seki E, Brenner DA and Karin M: A liver full of JNK: Signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 143:307–320. 2012. View Article : Google Scholar : PubMed/NCBI
14	Telbisz Á, Hegedüs C, Váradi A, Sarkadi B and Özvegy-Laczka C: Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: Effects of mutations in potential substrate and steroid binding sites. Drug Metab Dispos. 42:575–585. 2014. View Article : Google Scholar : PubMed/NCBI
15	Yoon CH, Kim MJ, Kim RK, Lim EJ, Choi KS, An S, Hwang SG, Kang SG, Suh Y, Park MJ and Lee SJ: c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. Oncogene. 31:4655–4666. 2012. View Article : Google Scholar : PubMed/NCBI
16	Jia Q, Zhang X, Deng T and Gao J: Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(⁺) CD133(⁺) liver cancer stem cells. Cell Reprogram. 15:143–150. 2013.PubMed/NCBI
17	Sukowati CH, Rosso N, Pascut D, Anfuso B, Torre G, Francalanci P, Crocè LS and Tiribelli C: Gene and functional upregulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterol. 12:1602012. View Article : Google Scholar
18	Sancho R, Nateri AS, de Vinuesa AG, Aguilera C, Nye E, Spencer-Dene B and Behrens A: JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J. 28:1843–1854. 2009. View Article : Google Scholar : PubMed/NCBI
19	Mucha SR, Rizzani A, Gerbes AL, Camaj P, Thasler WE, Bruns CJ, Eichhorst ST, Gallmeier E, Kolligs FT, Göke B and De Toni EN: JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand. Gut. 58:688–698. 2009. View Article : Google Scholar
20	Goodell MA: Multipotential stem cells and 'side population' cells. Cytotherapy. 4:507–508. 2002. View Article : Google Scholar
21	Qiu X, Wang Z, Li Y, Miao Y, Ren Y and Luan Y: Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. Cancer Lett. 323:161–170. 2012. View Article : Google Scholar : PubMed/NCBI
22	Ma S: Biology and clinical implications of CD133(⁺) liver cancer stem cells. Exp Cell Res. 319:126–132. 2013. View Article : Google Scholar
23	Lee JH, Shim JW, Choi YJ, Heo K and Yang K: The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression. Oncol Rep. 29:917–924. 2013.PubMed/NCBI
24	Carra E, Barbieri F, Marubbi D, Pattarozzi A, Favoni RE, Florio T and Daga A: Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle. 12:491–500. 2013. View Article : Google Scholar : PubMed/NCBI